An interventional study of expiratory muscle strentgh training (EMST) in Parkinson Disease, Multiple System Atrophy and Progressive Supranuclear Palsy, sponsored by Kliniken Beelitz GmbH. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Kliniken Beelitz GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.
Among the 264 studies in Parkinson Disease with a site in Germany, this one is the 119th largest by planned enrollment of the 198 interventional ones that give a count, is one of 11 that started in 2021, is one of 50 with no phase, reaches primary completion later than 2 of the 52 other live ones, and was the 208th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →41 of the 264 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany, France, Italy and 4 more countries
Ages 35–80
MODAG GmbH · Sites in Germany
Ages 50–75 · Healthy volunteers
H. Lundbeck A/S · Sites in Germany, United States, Czechia and 1 more country
Ages 40–85
University Hospital Muenster · Sites in Germany
Ages 18+
Integrative Research Laboratories AB · Sites in Germany, Bulgaria, Poland and 1 more country
Ages 50–90
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 53 · Phase 3 65 · Phase 4 19
First in 2001; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 106 across the 198 interventional studies, 195 across the 64 observational. Of the 186 that completed or were terminated, 73 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
173 of 264 have an industry lead sponsor. The 10 most frequent:
Kliniken Beelitz GmbH is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Kliniken Beelitz GmbH has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134634Parkinson's Clinic in Beelitz-HeilstattenEffect of a Vibrating Therapy Ball on Tremor and Daily Activities in Patients With Different Tremor Syndroms | 2026-11 |
| NCT06580977Heidelberg UniversityExploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease | 2026-12 |
| NCT07141719University of KielCollection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker | 2026-12-31 |
| NCT06602193Denali Therapeutics Inc.Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | 2027-03 |
| NCT06993571Universitätsklinikum Hamburg-EppendorfCerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor | 2027-03-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 264 studies in Parkinson Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an interventional therapy study designed to evaluate the efficacy of a two-week intervention, i.e. training with a specialized exhalation training device (called expiratory muscle strength training; EMST150 or EMST75; Aspire Products, Gainsville, FL) on swallowing function in patients with neurodegenerative Parkinsonian disorders. This study involves a routine endoscopic evaluation of swallowing (FEES) to diagnose dysphagia before and after the intervention. Between the two FEES, a two-week exhalation training program takes place, which the patients perform independently following instructions from a speech and lanuage pathologist. In addition demographic and disease-specific data and two questionnaires (Swallowing Disturbance Questionnaire for Parkinson's disease patients, SDQ-PD, and Swallowing specific Quality Of Life Questionnaire SWAL-QoL) are recorded.
This is an interventional therapy study designed to evaluate the efficacy of a two-week intervention, i.e. training with a specialized exhalation training device (called expiratory muscle strength training; EMST150 or EMST75; Aspire Products, Gainsville, FL) on swallowing function in patients with neurodegenerative Parkinsonian disorders. This study involves a routine endoscopic evaluation of swallowing (FEES) to diagnose dysphagia before and after the intervention. Between the two FEES, a two-week exhalation training program takes place, which the patients perform independently following instructions from a speech and lanuage pathologist. In addition demographic and disease-specific data and two questionnaires (Swallowing Disturbance Questionnaire for Parkinson's disease patients, SDQ-PD, and Swallowing specific Quality Of Life Questionnaire SWAL-QoL) are recorded.
Main hypothesis: Two weeks of EMST will lead to a significant improvement of the endoscopic dysphagia score in patients with neurodegenerative Parkinsonian disorders with endoscopically proven oropharyngeal dysphagia. Patients with idiopathic Parkinson's syndrome as well as its differential diagnoses, multiple system atrophy (MSA) and diseases from the group of 4repeat tauopathies, will be examined.
Idiopathic Parkinson's disease (PD):
More than 80% of all patients with PD develop clinically relevant dysphagia during the course of the disease. This can lead to a significant reduction in quality of life, decreased medication efficacy, malnutrition, dehydration, and ultimately aspiration pneumonia in affected patients, which is the most common cause of death in advanced PD patients. The cause of PD-associated dysphagia is a multifactorial genesis with impairment of dopaminergic and non-dopaminergic pathways of the central swallowing network and additional peripheral neuromuscular influences.
Multiple System Atrophy (MSA):
MSA is clinically associated with autonomic dysregulation manifested by neurogenic urinary bladder emptying dysfunction, orthostatic hypotension, sleep-related respiratory dysregulation, etc. in addition to Parkinsonian and/or cerebellar symptoms. Median survival after diagnosis is approximately 7 years. At disease onset, differentiation from idiopathic PD is difficult. However, relatively early in the course of the disease, symptoms such as a brittle voice or stridor may appear during normal breathing, which may be clues to the diagnosis of MSA. Since laryngeal abnormalities are associated with a significantly reduced life expectancy, they require special attention and diagnosis. In this regard, we have recently shown that a high prevalence of laryngeal movement abnormalities is present in MSA patients and can even be used to differentiate them from idiopathic Parkinson's disease. Swallowing function, the regulation of which is associated with autonomic centers of laryngeal function, is also often impaired early in patients with MSA. Because dysphagia can further limit quality of life and life expectancy, this symptom also requires early diagnosis and treatment. We could recently show that the dysphagia pattern also differs between PD and MSA.
4repeat tauopathies (4RT): The form of 4RT, also named progressive supranuclear gaze palsy (PSP) with all clinical subtypes, is a rapidly progressive neurodegenerative disease that leads to progressive functional impairment of cortical and subcortical function in affected individuals due to accumulation of tau protein in the brain. Due to the clinical variability of presentation, early diagnostic certainty is desirable, especially since human IgG4- antibodies directed against extracellular tau protein are currently in clinical trials to modify the course of the disease (see NCT03068468, NCT02985879). 4RT are also associated with swallowing and speech problems, and aspiration pneumonia is among the leading causes of death in this disease group. In addition, characteristic abnormalities may also occur due to dystonic dysinnervation of laryngeal muscles.
For dysphagia in atypical Parkinsonian syndromes, there are no proven interventional or drug therapy options. Previous studies in patients with PD had shown efficacy of a four-week training with a special expiratory muscle strength training (EMST) device. Both swallowing reliability and swallowing efficiency were improved. Studies on the efficacy of EMST on dysphagia of atypical Parkinsonian syndromes do not yet exist. Having demonstrated the efficacy of EMST in a 4-week intervention regime, the first aim is to test whether a shortened intervention duration of two weeks is also effective in patient with PD. In addition, this protocol will be performed in patients with MSA and 4RT to investigate effects, particularly on swallowing safety (reduction of penetration/aspiration events) and swallowing efficiency (reduction of pharyngeal residuals). Currently, all patients with PD, MSA, or 4RT at participating study sites receive a speech and language pathology examination and endoscopic diagnostics according to a defined protocol. In addition to phoniatric and swallowing-specific examinations, an endoscopic evaluation of swallowing (FEES) is routinely performed. Regarding the efficacy of EMST training on pharyngeal dysphagia in patients with PD, two randomized, placebo-controlled studies from recent years with n=60 and n=50 patients, respectively, have already shown an efficacy of training on both swallowing reliability and swallowing efficiency in PD patients. Relevant side effects or risks from training for the patients were not reported in the studies.
Studies using an EMST device have been conducted in recent years not only in patients with IPS, but also in patients with dysphagia due to other primary pathologies (e.g., amyotrophic lateral sclerosis, multiple sclerosis, stroke, etc.). In summary, a positive effect was shown, particularly on laryngeal muscle strengthening, which was reflected in an improvement in dysphagia.
The affected patients receive an initial endoscopic evaluation of the swallowing act in the clinical setting as part of routine diagnostics. In addition, oral and written patient education is provided. After written consent on the informed consent form, the following data are then collected anonymously prior to the start of the intervention:
This is followed by the individual adjustment of the EMST device for the respective patient. For this purpose, the maximum expiratory pressure (MEP) is first determined for the respective patient in the pulmonary function examination using a pressure manometer. 75% of the MEP is set for the subsequent training on the EMST device. This is then followed by the actual intervention. For this, the patient receives logopedic instruction on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days. Immediately following, items 3-10 will be collected again.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients diagnosed with PD will be allocated to this arm
Device: expiratory muscle strentgh training (EMST)
patients diagnosed with MSAwill be allocated to this arm
Device: expiratory muscle strentgh training (EMST)
patients diagnosed with 4RT will be allocated to this arm
Device: expiratory muscle strentgh training (EMST)
All patients undergo EMST training, and results will be compared between groups. After individual adjustment of the EMST device for each patient, the patient receives speeach adn instruction from a speech and language pathologist on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days.
dysphagia-score
improvement of dysphagia score observed on FEES after the intervention in all three groups. Three salient parameters of swallowing function are evaluated: 1. premature spillage 2. penetration-aspiration events 3. residue The scoring of these parameters is done separately using 3 ordinal 5-point scales (0- 4, from 0 = best to 4 = worst). Dysphagia severity, assessed by FEES, is classified according to a four-point scale (0-3) developed for patients with PD and atypical parkinsonism: 0 = no relevant dysphagia, 1. = mild dysphagia (premature spillage and/or residues without penetration/aspiration events), 2. = moderate dysphagia (penetration/aspiration events of one consistency), and 3. = severe dysphagia (penetration/aspiration events of two or more consistencies).
Time frame: 14 days
SDQ-PD score
improvement of SDQ-PD score after the intervention. SDQ comprises 15 items (score range 0.5 - 44.5 with higher scores indicating more severe swallowing disturbance) that are scored either 0 = symptom never appears, 1. = appears seldom (≤1/month), 2. = appears often (1-7/week), 3. = appears very often (\>7/week), item 15 was scored dichotomously: yes = 0.5
Time frame: 14 days
SWAL-QoL score
improvement of SWAL_QoL score after the intervention A 44item questionnaire (range 44 - 220) with lower scores indicating more severe impairment of swallowing-associated quality of life.
Time frame: 14 days
Plan to share: Yes — The study protocol, statistical analysis, informed consent form, and study data, including de-identified participant data, will be made available to others with publication upon formal request and receipt of a signed material transfer agreement. Requests should be directed to the corresponding author. Data will only be shared via individual secured network connections.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: after completion of data collection
Access criteria: Requests should be directed to the PI. Data will only be shared via individual secured network connections.
Started Nov 2021 (actual). Primary completion is estimated for Aug 2023, 21 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 21 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kliniken Beelitz GmbH